The upregulation of vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), and other pro-angiogenic proteins have led to development of therapies targeting angiogenesis and VEGF pathway members in RCC [7]. The gene discussed is VEGFA; the disease is renal cell carcinoma.